2025 Annual Meeting | C183 - Neurologic Complications of Novel Anti-neoplastic Therapies Including Immunotherapy
| 01:00 PM - 01:05 PM PDT | Introduction |
Introduction
Yazmin Odia, MD, MS, FAAN |
| 01:05 PM - 01:40 PM PDT | Speaker |
Neurological Complications of Cytotoxic Chemotherapy
Alexander Mohler, MD |
| 01:40 PM - 02:15 PM PDT | Speaker |
Neurological Complications of Immunotherapy
Jose R. McFaline-Figueroa, MD, PhD |
| 02:15 PM - 02:50 PM PDT | Speaker |
Neurological Complications of Radiation and Multimodal Therapy
Yazmin Odia, MD, MS, FAAN |
| 02:50 PM - 03:00 PM PDT | Q&A |
Panel Discussion
Yazmin Odia, MD, MS, FAAN, Jose R. McFaline-Figueroa, MD, PhD, Alexander Mohler, MD |
| Yazmin Odia, MD, MS, FAAN | Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile. |
| Jose R. McFaline-Figueroa, MD, PhD | Dr. McFaline-Figueroa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. The institution of Dr. McFaline-Figueroa has received research support from National Brain Tumor Society. The institution of Dr. McFaline-Figueroa has received research support from National Institutes of Health. The institution of Dr. McFaline-Figueroa has received research support from Robert Wood Johnson Foundation. |
| Alexander Mohler, MD | No disclosure on file |